mTOR抑制劑的全球市場:藥物類型，適應症，給藥途徑，流通管道，各地區 - 規模，佔有率，展望，機會分析(2022年～2030年)

全球mTOR抑制劑市場，來自法規機關的產品核可的增加預計促進在預測期間內的成長。

本報告提供全球mTOR抑制劑市場相關調查，市場動態，COVID-19影響，各市場區隔、地區的市場分析，競爭情形，主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

• 報告概要
• 摘要整理
• Coherent Opportunity Map(COM)

第3章 市場動態，法規，及趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 主要的開發
• PEST分析
• 法規情境
• 開發平台分析
• 新產品的銷售/核准
• 流行病學
• 市場趨勢

第4章 全球mTOR抑制劑市場-冠狀病毒(COVID-19)大流行的影響

• 經濟影響
• COVID-19流行病學
• 對COVID-19的政府舉措

第5章 全球mTOR抑制劑市場:各藥物類型

• 簡介
• Everolimus
• Temsirolimus
• Sirolimus

第6章 全球mTOR抑制劑市場:各適應症

• 簡介
• 腫瘤
• 免疫抑制
• 器官移植
• 其他

第7章 全球mTOR抑制劑市場:各給藥途徑

• 簡介
• 口服
• 靜脈內

第8章 全球mTOR抑制劑市場:各流通管道

• 簡介
• 醫院藥局
• 零售藥局
• 線上藥局

第9章 全球mTOR抑制劑市場:各地區

• 簡介
• 北美
• 美國
• 加拿大
• 南美
• 巴西
• 墨西哥
• 阿根廷
• 其他南美國家
• 歐洲
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 澳洲
• 韓國
• ASEAN
• 其他亞太地區
• 中東
• GCC
• 以色列
• 其他中東
• 非洲
• 南非
• 中非
• 北非

第10章 競爭情形

• 企業簡介
  • Novartis AG
  • Hikma Pharmaceuticals PLC.
  • Par Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Reddy's Laboratories Ltd.
  • Zydus Cadilla
  • Pfizer, Inc.
  • Biocon
  • Alkem Laboratories Ltd.
  • Accord Healthcare Inc.
  • Gland Pharma Ltd.
  • Apotex Inc.
  • Glenmark Pharmaceuticals Ltd.
• 分析師的見解

第11章 Section

Mammalian target of rapamycin (mTOR) is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. Mammalian target of rapamycin (mTOR) inibitors controls the cell division, and controls the growth of cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and it is being studied for use in other types of cancers. mTOR are indicated for the treatment of breast cancer, lymphangioleiomyomatosis, neuroendocrine carcinoma, organ transplant, pancreatic cancer, renal cell carcinoma, tuberous sclerosis complex and others. Mammalian target of rapamycin (mTOR), drugs are- Everolimus, Temsirolimus, and Sirolimus. Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.

Market Dynamics

Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period. For instance, in June 2021, Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress). Everolimus tablets will be in strength of 0.25mg, 0.5mg, and 0.75mg.

Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market. For instance, according to an article published by the U.S. Department of Health and Human Services, published in 2018, there were an estimated 582,727 people living with kidney and renal pelvis cancer in the U.S.

Key features of the study:

• This report provides an in-depth analysis of global mTOR inhibitors market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players

• It profiles leading players in the global mTOR inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

• Key companies covered as a part of this study include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.

• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

• The global mTOR inhibitors market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.

• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mTOR inhibitors

Detailed Segmentation:

• Global mTOR Inhibitors Market, By Drug Type:
  • Everolimus
  • Temsirolimus
  • Sirolimus
• Global mTOR Inhibitors Market, By Indication:
  • Oncology
  • Immunosuppressant
  • Organ Transplantation
  • Others
• Global mTOR Inhibitors Market, By Route of Administration:
  • Oral
  • Intravenous
• Global mTOR Inhibitors Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global mTOR Inhibitors Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Novartis AG*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Hikma Pharmaceuticals PLC.
  • Par Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Reddy's Laboratories Ltd.
  • Zydus Cadilla
  • Pfizer, Inc.
  • Biocon
  • Alkem Laboratories Ltd.
  • Accord Healthcare Inc.
  • Gland Pharma Ltd.
  • Apotex Inc.
  • Glenmark Pharmaceuticals Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Indication
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Development
• PEST Analysis
• Regulatory Scenario
• Pipeline Analysis
• New Product Launch/ Approval
• Epidemiology
• Market Trends

4. Global mTOR Inhibitors Market - Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Government Initiatives to Combat COVID-19

5. Global mTOR Inhibitors Market, By Drug Type, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Everolimus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Temsirolimus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Sirolimus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

6. Global mTOR Inhibitors Market, By Indication, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Immunosuppressant
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Organ Transplantation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global mTOR Inhibitors Market, By Route of Administration, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

8. Global mTOR Inhibitors Market, By Distribution Channel, 2017 - 2030 (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

9. Global mTOR Inhibitors Market, By Region, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
• U.S.
• Canada
• Latin America
  • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2017 - 2030 (US$ Mn)
• South Africa
• Central Africa
• North Africa

10. Competitive Landscape

• Company Profiles
  • Novartis AG
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Hikma Pharmaceuticals PLC.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Par Pharmaceutical
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Teva Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Reddy's Laboratories Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Zydus Cadilla
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Pfizer, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Biocon
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Alkem Laboratories Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Accord Healthcare Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Gland Pharma Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Apotex Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
  • Glenmark Pharmaceuticals Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About Us and Sales Contact